MAP2K7 and neoplasm: Nevertheless, because in mouse and human MEK inhibition causes only an average of 20% tumor volume reduction, and because 30% of individuals fail to respond to MEK inhibition (Gross et al, 2020), improvement over or alternatives to current MEK inhibition therapy may be useful clinically.